重组带状疱疹(GlaxoSmithKline Plc)(Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc)) - 在研适应症：疱疹后神经痛，带状疱疹，呼吸道合胞体病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、重组亚单位疫苗

别名

herpes zoster vaccine (recombinant, adjuvanted)、HZ/su、PED-HZ/su

+ [18]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染神经系统疾病其他疾病+ [1]

在研适应症

疱疹后神经痛带状疱疹呼吸道合胞体病毒感染+ [2]

非在研适应症

慢性淋巴细胞白血病新型冠状病毒感染白喉+ [9]

原研机构

GSK Plc

在研机构

GSK PlcGlaxoSmithKline Biologicals SAGlaxoSmithKline KK

+ [4]

非在研机构-

权益机构

重庆智飞生物制品股份有限公司

GSK Plc

最高研发阶段批准上市

首次获批日期

加拿大 (2017-10-13),

带状疱疹

最高研发阶段(中国)批准上市

特殊审评临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 13420648

关联

83

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的临床试验

NCT06890416

/ Active, not recruiting临床3期

A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

开始日期2025-04-04

申办/合作机构

Pfizer Inc.

NCT06763783

/ Enrolling by invitation临床4期

Vaccination in Patients With Inflammatory Rheumatic Diseases. The Impact of Anti-rheumatic Treatments on the Immunogenicity of Herpes-zoster Vaccine (Shingrix) and Protection Against Infection (HZ-REUMA)

The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD) compared to immunocompetent patients with IRD (controls).
Hypothesis:
The immunological disturbance as part of the rheumatic disease in combination with different immunomodulating treatments may impair vaccine response to non-live HZ vaccine (Shingrix) and thereby lead to an insufficient protection against infection.
Primary objective (outcome)
1. The impact of modern anti-rheumatic treatments including synthetic disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate and different biological treatments (anti-TNF, anti IL6r, anti-IL12/23/17, anti-CD20, anti-BlyS, anti-INFERON treatment, or targeted DMARDs (JAK-inhibitors) on antibody response elicited by two doses of subunit vaccine against herpes zoster (HZ) administrated 1-2 months apart in patients with IRD.
Secondary outcomes
2. The numbers and frequency of antigen specific CD4 2+ T cells expressing ≥2 or more activation markers (TNFalpha, INF-gama, interleukin-2 or CD40ligand)
3. Long-term immunogenicity of two doses of Shingrix in immunosuppressed patients with IRD measured 3 and 5 after vaccination
4. the tolerability of the vaccine, the impact on existing rheumatic disease, and possible association with onset of new autoimmune diseases
5. if vaccination against herpes zoster protects against infections in patients with inflammatory rheumatic diseases
Study Population Adult patients (18 years and older) with a clinically diagnosed inflammatory rheumatic disease and regularly followed at Skåne University Hospital, section for rheumatology in Lund/Malmö, Sweden are eligible for the study and will be offered vaccination free of charge. Control group comprises adult individuals with known inflammatory rheumatic disease without immunosuppressive treatment except for low dose prednisone (max 5 mg daily) .
Inclusion criteria:
* age ≥18 years (patients)
* regular follow up at Skåne University Hospital, section for rheumatology Lund/Malmö due to an inflammatory rheumatic disease (patients)
* receive active treatment with disease modifying anti-rheumatic drugs (DMARDs) such conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARDs or patients without active immunosuppressive treatment (controls)
Exclusions criteria
* age <18 years (patients)
* pregnancy (women of childbearing potential, WOCBP, are not excluded since all patients using DMARDs are advised to use a safe and effective contraceptive method)
* allergy/intolerability of any component in the vaccine
* active infection inclusive herpes zoster (shingles)
* received Shingrix vaccine previously
* ongoing treatment with any immunosuppressive drug for the other diseases Target enrolment/sample size: 240. Study start date: December, 17 2024- June 30, 2029

开始日期2024-12-17

申办/合作机构

Region Skåne Holding AB

ChiCTR2400090653

/ Suspended临床1期IIT

Clinical study on the protective mechanism of immune response of recombinant herpes zoster vaccine (CHO cell) based on multi-omics

开始日期2024-10-15

申办/合作机构-

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

3,839

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的文献（医药）

2025-12-31·Global Public Health

An intersectional analysis of social constraints and agency among sex workers in Tunisia during the COVID-19 pandemic; the community-based qualitative study EPIC-MENA

Article

作者: Bourhaba, Othmane ; Lorente, Nicolas ; Adami, Elisa ; Nabli, Montassar ; Karkouri, Mehdi ; Boulahdour, Nassima ; Torkhani, Sonia ; Beldi Chouikha, Khawla ; Castro Avila, Juliana ; Rojas Castro, Daniela ; Di Ciaccio, Marion

The economic, social and health impacts of the COVID-19 pandemic varied across population groups. This study aimed to provide a comprehensive view of the effects of socioeconomic constraints on sex workers' agency during the COVID-19 pandemic in Tunisia, using the analytical framework of intersectionality. We performed a thematic content analysis of semi-structured interviews conducted with sex workers (n = 19). Results highlighted the heavy burden of socioeconomic constraints on their agency, and specifically on their decision to continue sex work or not during the pandemic. The fact that there were fewer clients during the pandemic led to greater economic precarity, especially among mothers. Furthermore, interviewees - mostly cisgender male sex workers with same-sex practices - reported increased violence and discrimination by clients and the police. Participants also experienced difficulties accessing health care for themselves and for their children, including access to COVID-19 vaccination. This was especially true for women with a low educational level. Finally, sex workers' mental health was also strongly affected by the pandemic. Findings highlights the role of various intersecting socioeconomic conditions and structural vulnerabilities on sex workers' experience of the COVID-19 pandemic in Tunisia, in terms of health and their capacity to negotiate agency.

2025-12-31·Human Vaccines & Immunotherapeutics

Herpes zoster vaccination: Primary care provider knowledge, attitudes, and practices

Article

作者: Wang, Jinyi ; Stempniewicz, Nikita ; Sweeney, Carolyn ; Davenport, Eric

Primary care providers (PCPs) play a key role in vaccine recommendations and uptake, but limited information exists about PCP knowledge, attitudes, and practices regarding herpes zoster (HZ) vaccination. Clinical trials have shown that recombinant zoster vaccine (RZV) significantly reduces the risk of developing HZ. Hence, RZV is recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults aged ≥50 years and immunocompromised adults aged ≥19 years. However, RZV uptake varies across age groups, and is lower for adults aged 50-59 compared to those aged ≥60 years. Using a cross-sectional web-based survey, this study described provider knowledge of HZ risk factors, ACIP recommendations, attitudes toward HZ vaccination, and HZ vaccination practices/barriers. Among 301 licensed PCPs in the US, knowledge of HZ risk factors was high, but only 29% were fully aware of the ACIP recommendations. PCPs indicated that HZ vaccination was important for patients aged 50-59, 60-69, and ≥70 years, with importance increasing with advancing age. During a typical week, an average of 44% (standard deviation = 32%) of PCPs reported initiating a conversation about HZ vaccination among adults aged 50-59 years. Key perceived barriers to recommending HZ vaccines to adults were contraindications and insufficient time to assess risk factors, while perceived HZ vaccine administration challenges included patients' out-of-pocket costs and lack of motivation. Results suggest that PCPs may benefit from updated information about ACIP recommendations, while both patients and providers may benefit from streamlining the vaccination process and educational efforts focused on addressing perceived barriers.

2025-12-31·Human Vaccines & Immunotherapeutics

Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report

Article

作者: Tafuri, Silvio ; Stefanizzi, Pasquale ; Palmieri, Claudia ; Arbo, Anna ; Berti, Irene ; Moscara, Lorenza ; Noviello, Chiara

Epidermolysis bullosa is a rare genetic disorder characterized by skin fragility and blistering, resulting from mutations in dermal-epidermal junction structural proteins. Disease severity varies, with some cases involving extensive skin damage and complications secondary to chronic inflammation. Patients with immune-mediated dermatological conditions face a heightened risk of Herpes Zoster and Post-Herpetic Neuralgia, particularly during immunosuppressive treatments. A 10-year-old female with Recessive Dystrophic Epidermolysis Bullosa received off-label Recombinant adjuvanted Zoster Vaccine (RZV) - approved in individuals 18 years of age and older - before initiating Janus kinase inhibitor therapy, required to manage the underlying condition. Two standard RZV doses were administered on February 22 and April 29, 2024. No immediate vital sign alterations nor Adverse Events Following Immunization were documented in the first 7 days after immunization. A 6-month follow-up revealed no relevant emergent clinical events nor Herpes Zoster episodes. In conclusion, the case offers preliminary insights into RZV safety for high-risk pediatric patients. However, robust safety and efficacy studies are warranted to support the implementation of RZV for vulnerable individuals under 18 years of age.

382

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的新闻（医药）

2025-07-18

·Pharmaceutical Technology

FDA approves GSK’s prefilled syringe presentation of Shingrix

The prefilled syringe formulation is approved in the US for the vaccination of adults aged 50 and older,and individuals aged 18 and above at greater risk. Credit: Spino Kim/Shutterstock.com. The US Food and Drug Administration (FDA) has approved GSK’s Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles (herpes zoster). This development will streamline the process for healthcare professionals by eliminating the need to mix components before administration. Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials. The newly approved prefilled syringes are based on data demonstrating technical comparability between the new and original vaccine presentations. In line with current indications for Shingrix, the prefilled syringe formulation is approved in the US for the vaccination of adults aged 50 years and older, as well as individuals aged 18 and above at an increased risk of developing shingles due to immunodeficiency or immunosuppression. The US Centres for Disease Control and Prevention (CDC) advises that adults aged 50 and older should receive two doses of the vaccine to prevent shingles and its complications. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Those aged 19 and older who are immunodeficient or immunosuppressed should also receive two doses. GSK chief scientific officer Tony Wood stated: “At GSK, we are committed to advancing scientific innovation and delivering practical solutions that address the needs of the healthcare community. “This new presentation of Shingrix was developed to streamline the vaccination process, supporting healthcare professionals to protect against shingles, a disease that one in three US adults will develop in their lifetime.” The European Medicines Agency (EMA) is also reviewing this updated version of GSK’s shingles vaccine following acceptance of its filing in January 2025. GSK’s efforts to reintroduce its blood cancer drug Blenrep (belantamab mafodotin) faced a setback when the FDA raised eye safety concerns before a meeting to evaluate the therapy’s benefit-risk profile. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

上市批准疫苗

2025-07-17

·梅斯医学

npj Vaccines：带状疱疹和呼吸道合胞病毒疫苗联合使用可使痴呆风险下降37%

带状疱疹是由水痘带状疱疹病毒潜伏后激活引起的疾病，已知可导致神经炎症，近年来有越来越多流行病学证据表明接种带状疱疹疫苗与认知障碍风险降低相关。Shingrix作为一种含AS01佐剂的重组带状疱疹疫苗，相较于传统的减毒活疫苗Zostavax表现出更优的保护效果和免疫持久性。此外，呼吸道合胞病毒（RSV）感染近年来也被认定与认知功能下降相关，而新上市含AS01佐剂的RSV疫苗（Arexvy）激发强效免疫反应。由于AS01佐剂包含单磷脂A（MPL）和QS-21两种成分，可激活先天免疫信号通路，诱导IFN-γ产生等免疫反应，其对神经系统是否具有直接保护效应成为本研究关注的重点。传统观点认为免疫疫苗仅通过防止感染减低认知障碍风险，然而早期数据显示疫苗接种后数月内即见保护效应，防止感染不太可能完全解释此现象。近日，发表于npj Vaccines的一项大型回顾性队列研究，重点解析了Shingrix与Arexvy疫苗对认知障碍发病风险的影响。研究团队通过在美国联邦三级医疗电子健康记录数据库TriNetX中匹配分析了超过43万名60岁以上成年人，筛选出接受不同疫苗组合的个体群体。结果显示，相较于接受流感疫苗的对照组，接种AS01佐剂疫苗的群体在随访的18个月内显著降低了认知障碍的诊断风险。本项研究首次将RSV疫苗纳入比较，系统评估了佐剂作用对认知障碍防控的潜在影响，展现了疫苗佐剂不仅在感染病防治中，更在神经退行性疾病预防领域的应用潜力。本研究利用TriNetX美国合作网络的匿名电子健康记录，纳入2023年5月1日及以后接种疫苗的60岁及以上成年人。三大暴露组分别为仅接种AS01 RSV疫苗组（n=35,938）、仅接种AS01带状疱疹疫苗组（n=103,798）和同时接种两种疫苗组（n=78,658）。对照组为同期接种流感疫苗但未接种上述两种疫苗的个体。匹配时控制了66个协变量，包括年龄、性别、种族、既往疾病（如代谢病、心脑血管病、精神疾病等）、既往带状疱疹和流感疫苗接种史等，以降低混杂偏倚。排除了已确诊认知障碍相关疾病的个体。结果随访时间为疫苗接种后三个月至18个月，采用受限平均时间损失（Restricted Mean Time Lost, RMTL）比值作为主要统计指标，兼顾了风险随时间变化的动态情况。还进行性别分层分析与负控制结果评估，以验证效应的稳健性。研究结果认知障碍风险分析：与流感疫苗组相比，单独接种RSV疫苗者的认知障碍风险降低29%（RMTL比值0.71，95%CI 0.61–0.83，P=2.8×10⁻⁵），单独接种带状疱疹疫苗者降低18%（RMTL比值0.82，95%CI 0.74–0.91，P=0.00027），同时接种两者者降低37%（RMTL比值0.63，95%CI 0.55–0.72，P=4.7×10⁻¹²）。这分别对应在认知障碍诊断前多活87天、53天与113天的无病时间延长。双疫苗组与单疫苗组比较：无显著差异，提示保护作用接近饱和，无明显叠加效应。负控制与阳性控制：负控制（多种无关联急性疼痛疾病）未见显著差异，阳性控制（带状疱疹病毒感染率）如预期在带状疱疹疫苗接种组明显降低，增强结果的生物学合理性与方法学可信度。性别分层分析：未观察到性别对疫苗保护效应的调节作用，男女均显示相似的认知障碍风险降低。随访时间调整：纳入接种后三个月内确诊病例，结果一致，排除早期诊断偏差影响。图1 不同AS01佐剂疫苗与认知障碍、负控制疾病及带状疱疹感染风险的关联分析A. AS01疫苗组较流感疫苗组认知障碍风险显著下降；无论RSV疫苗、带状疱疹疫苗单独或联合接种B. 性别分层及包括接种前三个月病例的敏感性分析所示保护效应图2 认知障碍累计发病Kaplan-Meier曲线（RMTL风险比估计）RSV疫苗、带状疱疹疫苗和两种联合疫苗组均显著缓解了认知障碍的44月累计发病风险讨论本研究报道了AS01佐剂疫苗对认知障碍风险降低的首次系统性证据，特别是首次涵盖了RSV疫苗，这支持了佐剂本体参与认知障碍保护的假设。现有假设认为疫苗减少其靶向感染（带状疱疹病毒及RSV）进而降低神经炎症，从而减缓认知退化。但疫苗保护效应出现于接种后数月，发生感染病例减少的机制难以解释此短时间内效应，且同时接种两疫苗并未表现协同增效。此结果提示保护机制或许与AS01佐剂激活的特定免疫反应有关。AS01佐剂中具有激活Toll样受体4（TLR4）能力的单磷脂A（MPL）与植物提取物QS-21协同作用，可激活巨噬细胞、树突细胞，诱导IFN-γ产生，相关研究显示IFN-γ可能显著抑制阿尔茨海默病中的淀粉样斑块沉积，且在认知功能正常老人中IFN-γ水平与认知下降呈负相关。因此，AS01佐剂诱导的免疫机制提供了一种可能的神经保护路径。值得注意的是，单次AS01疫苗剂量即可能达到此机制的饱和，解释了疫苗联合未见额外保护效应。该研究规模庞大，控制了多种混杂因素，且辅以负控制结果和病毒感染发病率验证，增强了结果的信度。然而研究仍受限于EHR数据的固有缺陷，如诊断效度未知、社会经济与生活方式数据缺乏，以及疫苗剂次数据信息不完整等。RSV疫苗组中可能夹杂部分非AS01佐剂疫苗（估计24%），这意味着实际佐剂疫苗效应可能被低估。未来临床试验及免疫学机制研究将有助于验证AS01佐剂的认知保护潜能及其作用机制。参考资料：[1]Taquet M., Todd J.A., Harrison P.J. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. npj Vaccines. 2025;10:130. https://doi.org/10.1038/s41541-025-01172-3撰文 | 梅斯医学编辑 | 木白●热议！女子昏厥，医学院老师跪地救人被骂“袭胸”！网友叫嚣：换女的来按！当事人回应：我问心无愧！仅39%女性公共场合接受了心肺复苏●爆冷！上海海关学院录取位次，超去年上海交大医学院！为何宁去双非读海关，也不去名校学医？学校回应：今年已超同济，我们考公上岸概率高● 脱发补充维生素真的管用？Science重磅：这种常见的维生素是器官再生、毛发生长、修复皮肤的关键！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

疫苗临床研究

2025-07-17

·ETPharma

US FDA approves pre-filled version of GSK's shingles vaccine

Bengaluru: The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix , providing patients a more convenient option to receive the shot, the company said on Thursday. Shingles is a viral infection that causes a painful rash anywhere on the body and can sometimes lead to serious complications such as long-term nerve pain and vision loss. The infection is caused by the varicella-zoster virus (VZV), a type of herpes virus that remains in patients' bodies after they have had chickenpox and reactivates years later. The previous version of GSK's vaccine required a healthcare professional to mix the powdered form of the virus proteins with a liquid that boosts the immune response, before administration. The new form of Shingrix, which does not require the mixing, was approved based on data that showed both versions were equally effective. (Reporting by Siddhi Mahatole and Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)

疫苗上市批准

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重组带状疱疹(GlaxoSmithKline Plc)	J07BK03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疱疹后神经痛	欧盟	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	冰岛	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	列支敦士登	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	挪威	GlaxoSmithKline Biologicals SA	2018-03-21
带状疱疹	加拿大	GlaxoSmithKline, Inc.	2017-10-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道合胞体病毒感染	临床3期	美国	GSK Plc	2023-07-28
呼吸道合胞体病毒感染	临床3期	加拿大	GSK Plc	2023-07-28
新型冠状病毒感染	临床3期	美国	GSK Plc	2021-10-07
白喉	临床3期	美国	GSK Plc	2014-02-07
破伤风	临床3期	美国	GSK Plc	2014-02-07
百日咳	临床3期	美国	GSK Plc	2014-02-07
流感病毒感染	临床3期	美国	GSK Plc	2013-10-03
流感病毒感染	临床3期	加拿大	GSK Plc	2013-10-03
流感病毒感染	临床3期	德国	GSK Plc	2013-10-03
肿瘤	临床3期	美国	GSK Plc	2013-03-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02723773 (ZOE-LTFU, Literature \| NEWS) 人工标引	临床3期	带状疱疹	7,273	Herpes Zoster Vaccine GSK1437173A	積艱壓獵衊餘艱顧齋積(壓膚範鹽齋廠鹽獵蓋遞) = 憲繭膚鑰網鹽糧範糧積選顧憲鑰觸憲蓋鑰夢壓 (願遞網窪餘鹹窪襯構簾, 73.7 ~ 84.6) 更多	积极	2025-05-12
NCT05966090 (RSV-OA=ADJ-020, CTgov)	临床3期	带状疱疹 \| 呼吸道合胞体病毒感染	530	HZ/su vaccine+RSVPreF3 OA investigational vaccine (Co-administration Group)	選襯淵鑰顧積顧選鏇齋(製製觸簾積醖範製窪構) = 鑰獵觸願醖窪襯築鑰選網鏇積憲夢鬱鏇艱鑰築 (獵廠製範築鏇餘選簾鬱, 鹽鏇觸觸鹹襯膚淵襯壓 ~ 構願網顧繭齋憲製蓋獵) 更多	-	2025-04-01
				HZ/su vaccine+RSVPreF3 OA investigational vaccine (Control Group)	選襯淵鑰顧積顧選鏇齋(製製觸簾積醖範製窪構) = 獵鏇鑰遞構鹹鹽製願積網鏇積憲夢鬱鏇艱鑰築 (獵廠製範築鏇餘選簾鬱, 糧蓋糧遞鹹獵觸襯鹽鏇 ~ 廠鏇範構膚鹽齋夢範淵) 更多
NCT04091451 (CTgov)	临床3期	带状疱疹	1,430	Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) (HZ/su Group)	網顧築夢鏇膚簾繭醖淵 = 築鬱鏇顧範製憲鏇網艱選製網簾範顧鑰選願觸 (網蓋遞鑰鏇製簾淵醖築, 衊繭淵鑰繭鹽窪積繭憲 ~ 構顧憲醖願夢艱顧憲繭) 更多	-	2025-03-30
				Placebo (Placebo Group)	網顧築夢鏇膚簾繭醖淵 = 蓋構顧積鬱鹽獵鹹網鏇選製網簾範顧鑰選願觸 (網蓋遞鑰鏇製簾淵醖築, 製鬱繭醖鬱簾淵築範蓋 ~ 製網鬱遞獵繭積鹽顧淵) 更多
NCT03591770 (CTgov)	临床4期	溃疡性结肠炎	15	SHINGRIX (UC Patients on Tofacitinib Monotherapy)	鹹選願膚鹽壓積鏇遞繭 = 選構鏇膚齋鬱獵觸網築鑰蓋壓願鏇選鑰鏇鏇膚 (構齋鏇衊構醖鏇顧觸鏇, 觸網遞齋鹹襯窪膚獵衊 ~ 範網鹽蓋窪餘襯鑰衊鏇) 更多	-	2025-02-21
				SHINGRIX (UC Patients on Anti-TNF Monotherapy)	鹹選願膚鹽壓積鏇遞繭 = 膚餘膚簾蓋鬱襯網網鹹鑰蓋壓願鏇選鑰鏇鏇膚 (構齋鏇衊構醖鏇顧觸鏇, 壓願醖築鏇窪簾築遞夢 ~ 夢積築鑰鑰構鑰簾顧鬱) 更多
NCT04169009 (CTgov)	临床4期	带状疱疹	105	vOka varicella zoster virus (ZVL)+Zostavax (ZVL) (ZVL >5 Years Previously (Cohort 1))	衊範糧廠築網衊繭壓艱(製構顧鑰網齋襯網鑰鬱) = 衊壓獵積壓餘襯獵範遞窪鹹簾醖齋範網鹽積選 (夢遞憲襯衊糧製簾顧鬱, NA) 更多	-	2024-10-15
				ZVL (ZVL 6-12 Months Previously (Cohort 3))	衊範糧廠築網衊繭壓艱(製構顧鑰網齋襯網鑰鬱) = 蓋網簾蓋範衊襯獵範製窪鹹簾醖齋範網鹽積選 (夢遞憲襯衊糧製簾顧鬱, NA) 更多
NCT04869982 (CTgov)	临床4期	带状疱疹	6,138	RZV (RZV Group)	夢構顧艱糧淵繭構憲簾 = 範糧選鏇衊膚鑰廠淵醖觸蓋鹹衊選窪淵鏇構製 (觸獵窪壓糧鬱願遞選醖, 鑰醖顧廠範衊襯獵襯憲 ~ 壓願繭願繭餘願鑰鹹製) 更多	-	2024-09-19
				Placebo (Placebo Group)	夢構顧艱糧淵繭構憲簾 = 醖壓夢鹽積鏇壓壓餘選觸蓋鹹衊選窪淵鏇構製 (觸獵窪壓糧鬱願遞選醖, 醖遞製繭憲壓醖構選艱 ~ 網選糧齋淵蓋願鹹製窪) 更多
ESMO2024	N/A	肿瘤	-	Recombinant zoster vaccine (RZV, Shingrix®, GSK)	襯鏇憲鬱壓構簾選憲觸(壓憲廠願顧餘襯鹽顧鏇) = 艱選鹹鹽網鬱餘壓顧襯簾簾鬱壓鹹襯艱壓糧窪 (獵顧選顧齋窪製糧窪襯 )	-	2024-09-15
NCT04047979 (CTgov)	临床2期	带状疱疹 \| 水痘	38	Shingrix® (Younger Group)	願製廠觸鬱鹹鑰築願構(襯觸網醖獵積齋範醖獵) = 獵憲獵膚醖遞鑰夢觸網膚窪顧積醖築艱壓膚遞 (獵鬱製鬱齋繭齋蓋觸鹽, 0.8987) 更多	-	2024-07-30
				Shingrix® (Older Group)	願製廠觸鬱鹹鑰築願構(襯觸網醖獵積齋範醖獵) = 鑰顧簾鏇繭簾齋積範築膚窪顧積醖築艱壓膚遞 (獵鬱製鬱齋繭齋蓋觸鹽, 0.2983) 更多
Pubmed 人工标引	N/A	痴呆	-	Recombinant shingles vaccine	襯網憲顧蓋鹹艱範廠醖(膚構願繭願鏇蓋築窪顧) = 膚簾窪鏇憲觸餘艱壓觸積選鏇襯糧餘願蓋膚襯 (製窪構衊構網蓋餘製獵 )	积极	2024-07-25
EULAR2024	N/A	带状疱疹 \| 类风湿关节炎辅助	59,713	Adjuvanted Recombinant Zoster VaccineRZVuvanted Recombinant Zoster Vaccine (RZV (2-dose))	製鹽願鹹製鏇鏇繭蓋製(壓遞廠襯糧壓觸夢積糧) = 襯壓衊醖鑰淵鏇築選鬱簾醖餘願鬱艱繭製膚膚 (繭構壓壓膚鑰遞獵窪鏇 ) 更多	积极	2024-06-05
				Adjuvanted Recombinant Zoster Vaccine (non-RZV)	製鹽願鹹製鏇鏇繭蓋製(壓遞廠襯糧壓觸夢積糧) = 繭襯鑰糧鬱糧糧膚鬱範簾醖餘願鬱艱繭製膚膚 (繭構壓壓膚鑰遞獵窪鏇 )